Differentially Expressed Blood ARLNC1 in Combination with PCA3/PSA has Reassuring Clinical Applications in the Early Diagnosis of Prostate Cancer in Iranians: A pilot study
Urology Journal,
Vol. 22 No. 02 (2025),
2 March 2025
,
Page 75-82
https://doi.org/10.22037/uj.v21i.8144
Abstract
Purpose: Prostate cancer (PCA) is the second most common malignancy in Western countries. Long non-coding RNAs are new markers in disease diagnosis. Our aim of this study was to investigate liquid biopsy biomarkers with high specificity and sensitivity for early diagnosis of PCA patients in Iran.
Materials and methods: Blood specimens were collected from 29 PCA, 32 benign prostate hyperplasia (BPH), and 29 control (CTRL) individuals. Real-time PCR analyzed expression amounts of PSA, ARLNC1, UCA1, and PCA3. The ROC curve (receiver operating characteristic curve) analysis evaluated the diagnostic power of the examined molecules for PCA.
Results: There was a significant upregulation of PCA3 in PCA and BPH groups compared to the controls (p values for PCA3=< 0.001 and BPH vs. CTRL = 0.0015) while there was no significant difference between PCA and BPH individuals. A significant upregulation of ARLNC1 was seen in BPH group compared to the controls (p value = 0.0042). Also, PCA3 expression level showed a significant relationship with prostate volume.
There was no significant difference in UCA1 and PSA expression levels among the three groups (> 0.05). The
PCA3/PSA ratio was significantly increased in PCA and BPH individuals vs. the CTRL group with high sensitivity and specificity. The gene expression of PCA3 and ARLNC1 in the BPH group showed a significant relationship with age.
Conclusion: Our findings showed that in the diagnosis of prostate cancer, measuring the expression of PCA3, PSA, and ARLNC1 genes is necessary to determine the health, benign, or cancerous status of patients' prostate. Also, selecting the PCA3/PSA ratio provides a new approach for diagnosing this cancer if confirmed in a larger clinical sample size and functional studies.
- Prostate cancer; lncRNA; PSA; ARLNC1; UCA1; and PCA3
How to Cite
References
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49.
Jochems SHJ, Fritz J, Häggström C, Järvholm B, Stattin P, Stocks T. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. 2023 May;83(5):422-31.
Matsushita M, Fujita K, Nonomura N. Influence of Diet and Nutrition on Prostate Cancer. International journal of molecular sciences. 2020 Feb 20;21(4).
Conti DV, Darst BF, Moss LC, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Jan;53(1):65-75.
Vietri MT, D'Elia G, Caliendo G, et al. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. International journal of molecular sciences. 2021 Apr 4;22(7).
De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.
Tse LA, Lee PMY, Ho WM, et al. Bisphenol A and other environmental risk factors for prostate cancer in Hong Kong. Environ Int. 2017 Oct;107:1-7.
Doat S, Marous M, Rebillard X, et al. Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study. Int J Cancer. 2018 Oct 1;143(7):1644-51.
Tantengco OAG, Aquino IMC, de Castro Silva M, Rojo RD, Abad CLR. Association of mycoplasma with prostate cancer: A systematic review and meta-analysis. Cancer Epidemiol. 2021 Dec;75:102021.
Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol. 2021 Mar;15(3):790-800.
Tafuri A, Sebben M, Pirozzi M, et al. Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes. Urol Int. 2020;104(9-10):716-23.
Xu Y, Li L, Yang W, et al. Association between vasectomy and risk of prostate cancer: a meta-analysis. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):962-75.
Konishi N, Shimada K, Ishida E, Nakamura M. Molecular pathology of prostate cancer. Pathology international. 2005;55(9):531-9.
Hinata N, Fujisawa M. Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview. World J Mens Health. 2022 Apr;40(2):217-27.
Saw S, Aw T-C. Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population. Pathology. 2000;32(4):245-9.
Hoefner DM. Serum tumor markers: part II--practical considerations and limitations of testing. MLO: medical laboratory observer. 2006;38(2):10-1, 4.
Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. The Journal of urology. 1994;151(6):1571-4.
Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nature clinical practice Urology. 2005;2(4):174-82.
Vis A, Kranse R, Roobol M, Van Der Kwast TH, Schröder F. Serendipity in detecting disease in low prostate‐specific antigen ranges. BJU international. 2002;89(4):384-9.
Schröder F, Wildhagen M, Cancer’ RSGotERSoSfP. Screening for prostate cancer: evidence and perspectives. BJU international. 2001;88(8):811-7.
Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). The Prostate. 1999;39(4):316-22.
Schröder FH, Van Der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. The Journal of urology. 2000;163(3):806-12.
Schröder F, Wildhagen M. Low levels of PSA predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology. 2002;59(3):462.
Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. The Lancet. 2003;361(9363):1122-8.
Ornstein DK, Kang J. How to improve prostate biopsy detection of prostate cancer. Current Urology Reports. 2001;2(3):218-23.
Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010 Oct 6;1:150-77.
Alarcón-Zendejas AP, Scavuzzo A, Jiménez-Ríos MA, et al. The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):431-43.
Liu H, Xu Y, Yao B, Sui T, Lai L, Li Z. A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR. Cell death & disease. 2020;11(8):613.
Hassani B, Taheri M, Asgari Y, et al. Expression analysis of long non-coding RNAs related with FOXM1, GATA3, FOXA1 and ESR1 in breast tissues. Frontiers in oncology. 2021;11:671418.
Wang F-Y, Gu Z-Y, Gao C-J. Emerging role of long non-coding RNAs in normal and malignant hematopoiesis. Chinese Medical Journal. 2020;133(04):462-73.
De Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer research. 2002;62(9):2695-8.
Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine–a new perspective for detecting prostate cancer. European urology. 2004;46(2):182-7.
Ferreira LB, Palumbo A, de Mello KD, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC cancer. 2012;12:1-15.
van Bokhoven A, Varella‐Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. The Prostate. 2003;57(3):205-25.
De Luca S, Passera R, Bollito E, et al. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy. Anticancer Research. 2014;34(12):7159-65.
Lemos AEG, Ferreira LB, Batoreu NM, de Freitas PP, Bonamino MH, Gimba ERP. PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells. Tumor Biology. 2016;37:11339-48.
Zhang Y, Pitchiaya S, Cieślik M, et al. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 2018 Jun;50(6):814-24.
Yang Y, Liu KY, Liu Q, Cao Q. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer. Front Cell Dev Biol. 2021;9:660853.
Yao F, Wang Q, Wu Q. The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Manag Res. 2019;11:7685-96.
Yu Y, Gao F, He Q, Li G, Ding G. lncRNA UCA1 Functions as a ceRNA to Promote Prostate Cancer Progression via Sponging miR143. Mol Ther Nucleic Acids. 2020 Mar 6;19:751-8.
Hu M, Yang J. Down-regulation of lncRNA UCA1 enhances radiosensitivity in prostate cancer by suppressing EIF4G1 expression via sponging miR-331-3p. Cancer Cell Int. 2020;20:449.
Yang Z, Yu L, Wang Z. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res. 2016 Feb;28(1):65-71.
Matuszczak M, Schalken JA, Salagierski M. Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis. Cancers (Basel). 2021 Jul 5;13(13).
Zheng K, Dou Y, He L, et al. Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture. Oncology reports. 2015;34(5):2439-44.
Wang R, Wu Y, Yu J, Yang G, Yi H, Xu B. Plasma messenger RNAs identified through bioinformatics analysis are novel, non-invasive prostate cancer biomarkers. OncoTargets and therapy. 2020;13:541.
Moranova L, Stanik M, Hrstka R, Campuzano S, Bartosik M. Electrochemical LAMP-based assay for detection of RNA biomarkers in prostate cancer. Talanta. 2022;238:123064.
Saxena P, Trerotola M, Wang T, et al. PSA regulates androgen receptor expression in prostate cancer cells. The Prostate. 2012;72(7):769-76.
Ecke TH, Schlechte HH, Schiemenz K, et al. TP53 gene mutations in prostate cancer progression. Anticancer research. 2010;30(5):1579-86.
Bai VU, Kaseb A, Tejwani S, et al. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proceedings of the National Academy of Sciences. 2007;104(7):2343-8.
MORÁŇOVÁ L, STANÍK M, HRSTKA R, BARTOŠÍK M. ELECTROCHEMICAL ASSAY FOR DETECTION OF PROSTATE CANCER BIOMARKERS IN URINE. Book of abstracts; 2021; 2021. p. 100.
Mowayeiz KJ, Al-Wasiti EA, Hussein AG, Hasan NA, Al-Nasiri US. The Utility of PSA, PCA3 in Detection of Men with Prostate Tumors. Indian Journal of Public Health Research & Development. 2019;10(8).
Takayama K-i, Fujimura T, Suzuki Y, Inoue S. Identification of long non-coding RNAs in advanced prostate cancer associated with androgen receptor splicing factors. Communications Biology. 2020;3(1):393.
Shukla KK, Misra S, Sankanagoudar S, et al. Recent scenario of long non-coding RNAs as a diagnostic and prognostic biomarkers of prostate cancer. Urologic Oncology: Seminars and Original Investigations; 2020: Elsevier; 2020. p. 918-28.
Yao F, Wang Q, Wu Q. The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Management and Research. 2019;11:7685.
Ghafouri-Fard S, Taheri M. UCA1 long non-coding RNA: An update on its roles in malignant behavior of cancers. Biomedicine & Pharmacotherapy. 2019;120:109459.
Zhao X, Wang Y, He J, et al. LncRNA UCA1 maintains the low‐tumorigenic and nonmetastatic status by stabilizing E‐cadherin in primary prostate cancer cells. Molecular Carcinogenesis. 2020;59(10):1174-87.
- Abstract Viewed: 680 times
- 8144/pdf Downloaded: 343 times